These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 1233772)

  • 1. [Role of disturbed balance between plasma proteins and tissue proteins in essential arterial hypertension].
    Sumenković N
    Srp Arh Celok Lek; 1975; 103(11):1011-5. PubMed ID: 1233772
    [No Abstract]   [Full Text] [Related]  

  • 2. [Plasma protein changes in essential arterial hypertension: a new genetic marker for arterial hypertension?].
    Cloix JF; Devynck MA; Meyer P
    Ann Pediatr (Paris); 1982 Nov; 29(9):655-6. PubMed ID: 6960802
    [No Abstract]   [Full Text] [Related]  

  • 3. [Protein anomalies in chronic arterial hypertension; critical study of the methods utilized].
    ENSELME J; TIGAUD
    Ann Biol Clin (Paris); 1954; 12(3-4):196-226. PubMed ID: 13158913
    [No Abstract]   [Full Text] [Related]  

  • 4. Protein oxidation in mild essential hypertension.
    Caimi G; Mulè G; Hopps E; Carollo C; Lo Presti R
    Clin Hemorheol Microcirc; 2012; 50(3):193-5. PubMed ID: 22240348
    [No Abstract]   [Full Text] [Related]  

  • 5. Adiponectin in essential hypertension.
    Mallamaci F; Zoccali C; Cuzzola F; Tripepi G; Cutrupi S; Parlongo S; Tanaka S; Ouchi N; Kihara S; Funahashi T; Matsuzawa Y
    J Nephrol; 2002; 15(5):507-11. PubMed ID: 12455716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intramural and perivasal deposition of plasma proteins in experimented hypertension (author's transl)].
    Kunz J; Keim U; Braselmann H; Kreher C; Nitschkoff S
    Exp Pathol (Jena); 1973; 8(4):294-302. PubMed ID: 4272909
    [No Abstract]   [Full Text] [Related]  

  • 7. Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different degrees of essential hypertension.
    Simic DV; Mimic-Oka J; Pljesa-Ercegovac M; Savic-Radojevic A; Opacic M; Matic D; Ivanovic B; Simic T
    J Hum Hypertens; 2006 Feb; 20(2):149-55. PubMed ID: 16341053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma inhibitors of Na,K-ATPase: relation to salt balance and hypertension.
    Buckalew VM; Morris M; Campbell WG; Rauch AL
    Klin Wochenschr; 1987; 65 Suppl 8():133-8. PubMed ID: 3599798
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of endogenous Na+, K(+)-adenosine triphosphatase inhibitory factor in the regulation of membrane fluidity of erythrocytes in essential hypertension.
    Tsuda K; Shima H; Takeda J; Kimura K; Nishio I; Masuyama Y
    J Hypertens; 1992 Jul; 10(7):657-61. PubMed ID: 1321193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathophysiology and laboratory examinations of essential hypertension--a review of recent topics].
    Takahashi H; Nishimura M; Yoshimura M
    Rinsho Byori; 1990 May; 38(5):563-7. PubMed ID: 2143238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Characteristics of membrane and plasma proteins in the spontaneously hypertensive rat].
    Cloix JF; Devynck MA; Funck-Brentano JL; Meyer P
    C R Seances Acad Sci III; 1982 Mar; 294(13):661-4. PubMed ID: 6812864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The value of studying essential arterial hypertension with isotopic methods. Their application in arterial hypertension with low renin level].
    Olmer M; Salvadori JM; Paulin R; Sommer A; Marion J
    Nouv Presse Med; 1974 Feb; 3(5):233-6. PubMed ID: 4819942
    [No Abstract]   [Full Text] [Related]  

  • 13. [Plasma protein changes in essential hypertension: a new genetic marker of hypertension?].
    Cloix JF; Devynck MA; Meyer P
    Sem Hop; 1983 Apr; 59(15):1189-90. PubMed ID: 6306795
    [No Abstract]   [Full Text] [Related]  

  • 14. Arterial blood pressure and plasma and body electrolytes in idiopathic hyperaldosteronism: a comparison with primary hyperaldosteronism (Conn's syndrome) and essential hypertension.
    Lasaridis A; Brown JJ; Davies DL; Fraser R; Robertson JI; Lever AF
    J Hypertens; 1984 Aug; 2(4):329-36. PubMed ID: 6530544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Blood fluidity in essential hypertension, arterial occlusive disease and diabetic angiopathies].
    Sternitzky R; Hänsgen K; Podhaisky H
    Z Gesamte Inn Med; 1991 Nov; 46(16):610-4. PubMed ID: 1792802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased concentrations of a circulating sodium pump inhibitor in essential hypertension and uraemia and its partial purification from haemofiltrate.
    Wenzel M; Heidrich E; Kirch U; Moreth-Wolfrat K; Wizemann V; Schoner W
    Physiol Bohemoslov; 1990; 39(1):79-85. PubMed ID: 2165269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of DOCA-salt treatment duration and anteroventral third ventricle lesions on a plasma-borne sodium pump inhibitor in rats.
    Songu-Mize E; Bealer SL; Caldwell RW
    J Hypertens; 1987 Aug; 5(4):461-7. PubMed ID: 3668248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma brain natriuretic peptide and C-type natriuretic peptide in essential hypertension.
    Cheung BM; Brown MJ
    J Hypertens; 1994 Apr; 12(4):449-54. PubMed ID: 8064169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor binding proteins in arterial hypertension: relationship to left ventricular hypertrophy.
    Díez J; Laviades C; Martínez E; Gil MJ; Monreal I; Fernández J; Prieto J
    J Hypertens; 1995 Mar; 13(3):349-55. PubMed ID: 7542683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Renin-angiotensin-aldosterone system in essential hypertension. Inappropriately high plasma aldosterone in young patients with severe hypertension and in older hypertensives].
    Vetter H; Zumkley H; Glänzer K; Witassek F; Wollnik S; Vetter W
    Schweiz Med Wochenschr; 1980 Dec; 110(50):1938-41. PubMed ID: 7010579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.